Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

“The next new $1trn stock will be…”

There are a very select few stocks that have seen their market cap exceed $1trn. And those that bought shares before that milestone will be very happy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since The Motley Fool’s mission statement is to make the world smarter, happier and richer, we asked some of our freelance writers which US stocks they think might be next to crack the $1trn threshold — potentially making shareholders very happy indeed!

Berkshire Hathaway

What it does: Warren Buffett’s diversified holding company uses an insurance float model to invest in dozens of businesses.

By Charlie CarmanBerkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) has broken the $700bn market capitalisation barrier, but it’s never reached the trillion-dollar threshold. I think that’s only a matter of time. As I write, the company would need to deliver a 36% share price gain to achieve this landmark.

From 1965 to 2022, Berkshire Class A stock achieved a 19.8% compound annual growth rate. Returns have slowed since the turn of the millennium, but the annual average remains firmly in double digits.

Recent results have been encouraging. In the first quarter, Berkshire posted a $35.5bn profit and accelerated its share repurchases, buying back $4.4bn of its own stock.

A major risk facing the company is the potential loss of investor confidence that could result from its CEO’s looming departure. After all, Buffett is 92.

However, his successor Greg Abel has already taken on many responsibilities, suggesting the handover could be less problematic than some fear.

Charlie Carman owns shares in Berkshire Hathaway. 

Berkshire Hathaway

What it does: Berkshire Hathaway is a diversified conglomerate that operates in sectors including insurance and retail and owns a stock portfolio.

By Christopher Ruane. The famed investor Warren Buffett has built Berkshire Hathaway over the course of decades.

Since taking the company over in 1965, Buffett has achieved a compounded annual gain of 19.8% in its per-share market value.

Some years are markedly better than others. In general, I think the defensive nature of many Berkshire businesses means that it can do well when the wider market stumbles. In 2007, for example, its compounded annual gain was 28.7% while the benchmark S&P 500 only achieved 5.5%.

The economy looks weak again to me, but one big difference is Berkshire’s massive position in Apple. If tech stocks including Apple fall, that could hurt Berkshire’s share price.

But I think the company’s broadly defensive asset base and Buffett’s steady hand on the tiller could help Berkshire ride out the next storm well. Its shares have risen 81% in five years and today the market capitalisation is $736bn.  

Christopher Ruane does not own shares in any of the companies mentioned.

Eli Lilly

What it does: Eli Lilly is a global healthcare company with products spanning oncology, immunology, diabetes and neurology.

By Ben McPoland. I think biopharma giant Eli Lilly (NYSE: LLY) could become the newest $1trn stock. Its market cap of $435bn already makes it one of the largest companies in the world.

The firm has a packed late-stage pipeline of potential blockbusters. One is its Alzheimer’s treatment, donanemab,which has successfully slowed memory and thinking decline in a rigorous phase 3 trial.

A second is Mounjaro, which is a medicine already used by people with type 2 diabetes. It is currently being assessed by US regulators and the NHS as a repositioned treatment for weight loss.

Needless to say, a proven and safe treatment for obesity (which is a global health issue) could be a huge deal for the company. Indeed, some analysts think it could become the biggest selling drug ever. And it could be approved by the end of this year. 

One risk is that this huge potential is already priced into the stock, with its trailing P/E of 72. Any disappointing regulatory news could hit the share price hard.  

Ben McPoland does not own shares in Eli Lilly.

The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

2 investment trusts from the FTSE 250 worth digging into for passive income

Plenty of FTSE 250 investment trusts offer dividend growth potential over the long run. So why does this writer like…

Read more »

Warhammer World gathering
Investing Articles

The Games Workshop share price is up 38% in a year. Is there any value left?

The Games Workshop share price has risen by more than a third in a year. Our writer considers what might…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This AI growth stock could rise 60%-70%, according to Wall Street analysts

This growth stock has lagged the market in 2025. However, Wall Street analysts expect it to play catch up next…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Prediction: here’s where the red-hot Lloyds share price and dividend yield could be next Christmas

Harvey Jones has done brilliantly out of the Lloyd share price over the last year. Now he's wondering whether he'll…

Read more »

Female Tesco employee holding produce crate
Investing Articles

Up 23% in 2025, are Tesco shares still capable of providing attractive returns?

Tesco shares have produced two to three years’ worth of investment returns in just 11 months. Can they continue to…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Is this 8.5% yielding FTSE 100 stock a passive income star or deadly value trap?

Harvey Jones shows just how much passive income investors can get from FTSE 100 dividend shares, but would like to…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

2 FTSE 100 shares I like better than Rolls-Royce right now

This writer owns Rolls-Royce shares and is very happy with their blockbuster performance. But which two Footsie shares does he…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

A £1,847 monthly passive income needs this much in a Stocks and Shares ISA…

How much is needed in a Stocks and Shares ISA to deliver reliable passive income for years and decades? Our…

Read more »